JANX
Janux Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$16.59
−1.60%Price chart
Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18
Key dataSep 18, 2026
Open$16.82
From 52W high−52.25%
Volume2.41M
Market cap$1.01B
P/E (TTM)—
P/S (TTM)31.8x
Div yield—
Key dataSep 18, 2026
Open
$16.82
From 52W high
−52.25%
Volume
2.41M
Market cap
$1.01B
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−0.6x
P/E (TTM)
—
RSI (14)
41.7
MomentumView details →
1D Return
−1.60%
YTD Return
+19.35%
SummaryUpdated Jun 1, 2026
Janux Therapeutics, Inc. (NASDAQ:JANX) is a clinical-stage biopharmaceutical company founded in 2017 and headquartered in La Jolla, California. The company went public in June 2021 and focuses on developing innovative cancer immunotherapies using its proprietary platform technologies. Janux specializes in creating next-generation T-cell engager therapies designed to harness the body's immune system to fight cancer more effectively than traditional treatments.
Similar companies
Latest newsMore news →
Janux Therapeutics dosed the first patient in a Phase 1 clinical trial of JANX013, a PSMA-targeted tumor-activated CD28 co-stimulatory bispecific, in patients with metastatic castration-resistant prostate cancer.6d agoJanux Therapeutics reported a second-quarter net loss of $0.35 per share, missing the Zacks Consensus Estimate of a $0.26 loss, and compared to a $0.55 loss per share in the same quarter last year.45d ago